EUVIMEDEUVIMED entdecken
Crossref

3-hydroxyanthranilic acid analog mitigates ischemia-reperfusion injury by inhibiting cardiomyocyte ferroptosis through the activation of Nrf2/HO-1/GPX4

Hao-Yuan Yang, Zi-Yan Liu, Zhen-Qiang Xu, Lin-Song Teng, Xie-Huang Sheng, Gang Zhang, Fu-Sheng Zhang

International Immunopharmacology · 2025-09 · 162 · 115117

DOI: 10.1016/j.intimp.2025.115117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025-09. Verfasst von Hao-Yuan Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250021 Jinan, Shandong, China. Hauptthemen laut MEDLINE: Ferroptosis, Myocytes, Cardiac, Myocardial Reperfusion Injury, 3-Hydroxyanthranilic Acid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial ischemia-reperfusion injury (MIRI) is a widespread condition that causes cardiac dysfunction, myocardial cell loss, and fibrosis. It is associated with substantial global morbidity, disability, and mortality, placing a considerable strain on healthcare systems and economies. 3-Hydroxyanthranilic acid (3-HA), an endogenous intermediates of tryptophan metabolism, exhibits modest anti-ferroptotic effects; however, its limited efficacy hinders its clinical applicability. Here, we report ethyl 3-hydroxydiaminobenzoate (E3-H), a novel analog of 3-HA, which demonstrates a striking 100-fold increase in efficacy in the RSL3-induced ferroptosis model. E3-H exhibits broad-spectrum efficacy, effectively suppressing ferroptotic cell death across multiple cell types and diverse ferroptosis inducers. In vivo, E3-H provides superior protection against myocardial ischemia-reperfusion injury (MIRI) compared to 3-HA, mitigating ferroptosis, reducing cardiac damage, and enhancing anti-inflammatory responses. Mechanistically, E3-H inhibits ferroptosis by upregulating the Nrf2/HO-1/GPX4 signaling axis, a critical regulator of cellular antioxidant defense and ferroptosis. These findings highlight the potential of E3-H as a promising therapeutic strategy for treating MIRI and suggest a new avenue for ferroptosis-targeted interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisMyocytes, CardiacMyocardial Reperfusion Injury3-Hydroxyanthranilic AcidAnimalsNF-E2-Related Factor 2MiceHeme Oxygenase-1Phospholipid Hydroperoxide Glutathione PeroxidaseMaleMice, Inbred C57BLHumansSignal Transduction

Stichwörter der Autor:innen

3-Hydroxyanthranilic acidFerroptosisMyocardial ischemia-reperfusion injuryTherapeutic targets

Substanzen

NF-E2-Related Factor 2Heme Oxygenase-1Phospholipid Hydroperoxide Glutathione Peroxidase3-Hydroxyanthranilic AcidNfe2l2 protein, mouseglutathione peroxidase 4, mouse

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250021 Jinan, Shandong, China.
  • College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Shandong Provincial Key Laboratory of Clean Production of Fine Chemicals, Shandong No…
  • Department of Orthopedic Surgery, The Second Clinical College of Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
  • Department of Cardiovascular Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250021 Jinan, Shandong, China. Electronic address: surgeonzg@163.com.
  • Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250021 Jinan, Shandong, China. Electronic address: fushengzhang@163.com.

Zitieren

APA

Yang, H. Y., Liu, Z. Y., Xu, Z. Q., Teng, L. S., Sheng, X. H., Zhang, G., & Zhang, F. S. (2025). 3-hydroxyanthranilic acid analog mitigates ischemia-reperfusion injury by inhibiting cardiomyocyte ferroptosis through the activation of Nrf2/HO-1/GPX4. International Immunopharmacology, 162, 115117. https://doi.org/10.1016/j.intimp.2025.115117

Vancouver

Yang HY, Liu ZY, Xu ZQ, Teng LS, Sheng XH, Zhang G, et al. 3-hydroxyanthranilic acid analog mitigates ischemia-reperfusion injury by inhibiting cardiomyocyte ferroptosis through the activation of Nrf2/HO-1/GPX4. International Immunopharmacology. 2025;162:115117. doi:10.1016/j.intimp.2025.115117

BibTeX
@article{Yang2025,
  author = {Yang, Hao-Yuan and Liu, Zi-Yan and Xu, Zhen-Qiang and Teng, Lin-Song and Sheng, Xie-Huang and Zhang, Gang and Zhang, Fu-Sheng},
  title = {3-hydroxyanthranilic acid analog mitigates ischemia-reperfusion injury by inhibiting cardiomyocyte ferroptosis through the activation of Nrf2/HO-1/GPX4},
  journal = {International Immunopharmacology},
  year = {2025},
  volume = {162},
  pages = {115117},
  doi = {10.1016/j.intimp.2025.115117}
}
Kostenlos starten →